Pharsight

Drug patents opposed in 2017

Drug patents opposed in 2017 at the European Patent Office (EPO).

Patent Number Patent Title Company Recent Opposition Date Recent Opposition By Activity Alert
EP2999752B1 Metallic lustre pigments based on substrate flakes with a thickness of 1-50 nm SCHLENK METALLIC PIGMENTS 29 Dec, 2017
ECKART
(and 1 more)
EP2664343B2 Suppression of cancer IPSEN BIOINNOVATION 28 Dec, 2017
ALLERGAN
EP1663297B2 Hemostatic compositions containing sterile thrombin ETHICON 22 Dec, 2017
BAXTER
EP2854768B1 Pharmaceutical compositions of pemetrexed FRESENIUS KABI ONCOLOGY 22 Dec, 2017
GENERICS UK
(and 2 more)
EP2762140B1 Treatment of solid brain tumours with a rapamycin derivative NOVARTIS AG 22 Dec, 2017
(Expiration: Feb, 2022)
GENERICS UK
(and 1 more)
EP3050556B1 Process for manufacturing a pharmaceutical preparation containing glatiramer acetate TEVA PHARMACEUTICAL INDUSTRIES LTD 22 Dec, 2017
(Expiration: Sep, 2035)
GENERICS UK TRADING MYLAN
(and 1 more)
EP2776129B2 Calcimimetics and methods for their use KAI PHARMACEUTICALS 22 Dec, 2017
HEXAL SANDOZ
EP2460817B1 PCV2 immunogenic compositions and methods of producing such compositions BOEHRINGER INGELHEIM VETMEDICA INC 22 Dec, 2017
(Expiration: Dec, 2025)
INTERVET
EP3045471B1 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation FERRING BV 22 Dec, 2017
(Expiration: Apr, 2029)
MERCK SERONO
EP2558116B2 Agent for locally treating cervical dysplasias GENERAL VECTORS 21 Dec, 2017
GLAXOSMITHKLINE BIOLOGICALS
EP2056832B1 Compositions, suitable for oral administration, comprising a triazolo [4, 5-d]pyrimidin derivate ASTRAZENECA AB 21 Dec, 2017
(Expiration: Aug, 2027)
HEXAL BIOTECH
(and 2 more)
EP2493498B1 Purification of staphylococcus aureus type 5 and type 8 capsular saccharides GLAXOSMITHKLINE BIOLOGICALS SA 21 Dec, 2017
(Expiration: Nov, 2030)
PFIZER
EP2637664B1 Compositions and methods of treating pulmonary hypertension GILEAD SCIENCES INC 21 Dec, 2017
(Expiration: Oct, 2031)
TEVA PHARMACEUTICAL INDUSTRIES
(and 5 more)
EP2532676B1 Protease-regulated antibody BAYER PHARMA 21 Dec, 2017
WHITE
EP2575770B1 Process for making dry and stable hemostatic compositions BAXTER 20 Dec, 2017
FERROSAN MEDICAL DEVICES
(and 1 more)
EP1731152B1 Sustained analgesia achieved with transdermal delivery of buprenorphine EURO CELTIQUE SA 20 Dec, 2017
(Expiration: Feb, 2018)
TESA LABTEC
(and 2 more)
EP2477611B1 (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability SANOFI SA 19 Dec, 2017
(Expiration: Sep, 2030)
COOKE
(and 2 more)
EP1845956B1 Break-resistant delayed-release forms of administration GRUENENTHAL GMBH 19 Dec, 2017
(Expiration: Feb, 2026)
G L PHARMA
EP3053571B1 Process for the preparation of a particulate dental filler composition DENTSPLY DETREY 19 Dec, 2017
KULZER
EP2261184B8 Lithium silicate glass ceramic IVOCLAR VIVADENT 19 Dec, 2017
VITA ZAHNFABRIK H RAUTER
EP2680880B2 Vaccination in newborns and infants CUREVAC 18 Dec, 2017
STRAWMAN
EP2680881B1 Vaccination in elderly patients CUREVAC AG 18 Dec, 2017
(Expiration: Feb, 2032)
STRAWMAN
EP2346475B2 Personal care compositions providing enhanced cooling sensation THE PROCTER & GAMBLE 15 Dec, 2017
COLGATE PALMOLIVE
EP2258847B2 Futher novel forms of interfering rna molecules SILENCE THERAPEUTICS 15 Dec, 2017
SANOFI
(and 2 more)
EP1798285B1 Methods and medicament for inhibition the expression of a defined gene ALNYLAM EUROPE AG 15 Dec, 2017
(Expiration: Jan, 2020)
SILENCE THERAPEUTICS
EP2519231B1 Proteasome inhibitors for treating cancer JANSSEN PHARMACEUTICA NV 14 Dec, 2017
(Expiration: Oct, 2030)
ACCORD HEALTHCARE
EP1976558B1 Pcv2 immunogenic composition for lessening clinical symptoms in pigs BOEHRINGER INGELHEIM VETMEDICA INC 14 Dec, 2017
(Expiration: Dec, 2026)
ELI LILLY
EP2410981B2 Dry powder formulations and methods for treating pulmonary diseases PULMATRIX OPERATING 12 Dec, 2017
TEVA UK
EP2694267B2 Continuous process of making an article of dissolution upon use to deliver surfactants THE PROCTER & GAMBLE 11 Dec, 2017
HENKEL
EP2421504B2 Paediatric solutions comprising a beta-blocker PIERRE FABRE DERMATOLOGIE 08 Dec, 2017
AECHTER
EP2044947B1 MVA-based compositions and methods for inducing an immune response against influenza OXFORD UNIVERSITY INNOVATION LTD 08 Dec, 2017
(Expiration: Dec, 2027)
IMUTEX
EP2688877B1 Solid state forms of cabazitaxel and processes for preparation thereof TEVA PHARMACEUTICALS 08 Dec, 2017
MACKERT
EP2988756B2 Contrast medium formulation and related preparation method GUERBET 08 Dec, 2017
MASCHIO & SOAMES
EP2627676B1 Novel cellulose ethers and their use DOW 08 Dec, 2017
SHIN ETSU CHEMICAL
EP2872497B2 Chromanyl derivatives for treating mitochondrial disease KHONDRION 08 Dec, 2017
SULFATEQ
EP2723319B1 Composition comprising an onion extract and liposomes MERZ PHARMA 07 Dec, 2017
FARCO PHARMA
EP2637670B2 Prevention of adverse effects caused by cd3 specific binding domains AMGEN RESEARCH MUNICH 07 Dec, 2017
LINDIS BIOTECH
(and 1 more)
EP2668175B2 Process SHIELD TX UK 07 Dec, 2017
TEVA PHARMACEUTICAL INDUSTRIES
EP2381797B2 Animal feed additive and animal feed comprising alkyl esters of medium chain fatty acids, and their use in animal feed NUTRECO NEDERLAND 06 Dec, 2017
NUTRITION SCIENCES
EP2347770B2 Process for producing an injectable pharmaceutical preparation VERGELL MEDICAL 06 Dec, 2017
VOSSIUS & PARTNER PATENTANWLTE RECHTSANWLTE MBB
EP2996777B1 Oral care compositions UNILEVER 01 Dec, 2017
COLGATE PALMOLIVE
EP2445911B1 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors GALAPAGOS 01 Dec, 2017
GENERICS UK
EP2040683B2 Pharmaceutical composition containing a tetrahydrofolic acid BAYER 01 Dec, 2017
LABORATORIOS LON FARMA
EP2717845B1 Styling agents having maximum hold HENKEL 01 Dec, 2017
LOREAL
EP2646470B1 Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier F HOFFMANN LA ROCHE AG 01 Dec, 2017
(Expiration: Nov, 2031)
SANOFI
(and 2 more)
EP2345433B1 Tissue plug 3D MATRIX LTD 30 Nov, 2017
(Expiration: Oct, 2029)
POTTER CLARKSON
EP2791163B1 Process for t cell expansion ALLOVIR 30 Nov, 2017
STRAWMAN
EP2624859B1 Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy MEDIMMUNE LTD 30 Nov, 2017
(Expiration: Sep, 2031)
STRAWMAN
EP2496700B1 Nucleic acid-containing lipid particles and related methods UNIVERSITY OF BRITISH COLUMBIA 30 Nov, 2017
(Expiration: Nov, 2030)
WITHERS & ROGERS
(and 1 more)
EP2792373B1 Ultra high molecular weight polyethylene articles and methods of forming ultra high molecular weight polyethylene articles ZIMMER GMBH 29 Nov, 2017
(Expiration: Aug, 2025)
AESCULAP
EP2432454B1 Compositions for continuous administration of dopa decarboxylase inhibitors NEURODERM 29 Nov, 2017
TEVA
EP2448548B1 Method for improving the appearance of hyperpigmented spot(s) using an extract of laminaria saccharina PROCTER AND GAMBLE CO 29 Nov, 2017
(Expiration: Jul, 2030)
UNILEVER
EP2266958B1 Antiviral agent SHIONOGI AND CO LTD 28 Nov, 2017
(Expiration: Aug, 2022)
MERCK
EP2301961B9 Sclerostin epitopes AMGEN 22 Nov, 2017
JAMES POOLE
EP2425824B1 Pharmaceutical preparation containing oxycodone and naloxone EURO CELTIQUE SA 09 Nov, 2017
(Expiration: Apr, 2023)
G L PHARMA
(and 10 more)
EP2425821B1 Pharmaceutical preparation containing oxycodone and naloxone EURO CELTIQUE SA 07 Nov, 2017
(Expiration: Apr, 2023)
ETHYPHARM
(and 10 more)
EP2949335B1 Low frequency glatiramer acetate therapy YEDA RESEARCH AND DEVELOPMENT CO LTD 04 Oct, 2017
(Expiration: Aug, 2030)
G L PHARMA
(and 5 more)
EP2841431B2 Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same OTSUKA PHARMACEUTICAL 28 Sep, 2017
GEORG KALHAMMERSTEPHAN TEIPEL